Eli Lilly and Company (NYSE:LLY) is SeaTown Holdings Pte. Ltd.’s 8th Largest Position

SeaTown Holdings Pte. Ltd. grew its position in Eli Lilly and Company (NYSE:LLY) by 34.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,348 shares of the company’s stock after buying an additional 3,170 shares during the period. Eli Lilly and Company accounts for approximately 6.5% of SeaTown Holdings Pte. Ltd.’s investment portfolio, making the stock its 8th largest position. SeaTown Holdings Pte. Ltd.’s holdings in Eli Lilly and Company were worth $9,533,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in LLY. Beck Bode LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $15,036,000. XTX Topco Ltd purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $546,000. Westwood Holdings Group Inc. grew its stake in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. Westwood Holdings Group Inc. now owns 3,912 shares of the company’s stock valued at $3,542,000 after buying an additional 73 shares during the period. Commonwealth Financial Services LLC lifted its holdings in shares of Eli Lilly and Company by 2.4% in the 2nd quarter. Commonwealth Financial Services LLC now owns 822 shares of the company’s stock worth $755,000 after acquiring an additional 19 shares during the last quarter. Finally, Certified Advisory Corp lifted its holdings in shares of Eli Lilly and Company by 3.6% in the 2nd quarter. Certified Advisory Corp now owns 4,064 shares of the company’s stock worth $3,679,000 after acquiring an additional 142 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on LLY. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Bank of America restated a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Wolfe Research began coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, January 1st. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.

Eli Lilly and Company Trading Down 4.1 %

NYSE LLY opened at $726.24 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm has a market cap of $689.43 billion, a PE ratio of 78.51, a P/E/G ratio of 1.66 and a beta of 0.41. Eli Lilly and Company has a one year low of $612.70 and a one year high of $972.53. The firm’s fifty day moving average is $781.14 and its two-hundred day moving average is $854.04.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the firm earned $0.10 earnings per share. The company’s revenue was up 20.4% compared to the same quarter last year. Analysts expect that Eli Lilly and Company will post 13.14 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a stock repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.